These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15916502)

  • 21. Raloxifene and risk of vertebral fracture in postmenopausal women.
    Halbekath J; Becker-Brüser W; Wille H
    JAMA; 2000 May; 283(17):2236-7. PubMed ID: 10807376
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
    Usall J; Huerta-Ramos E; Labad J; Cobo J; Núñez C; Creus M; Parés GG; Cuadras D; Franco J; Miquel E; Reyes JC; Roca M;
    Schizophr Bull; 2016 Mar; 42(2):309-17. PubMed ID: 26591005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
    Jacobsen DE; Melis RJ; Verhaar HJ; Olde Rikkert MG
    J Am Med Dir Assoc; 2012 Feb; 13(2):189.e1-7. PubMed ID: 21741883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
    Delmas PD; Ensrud KE; Adachi JD; Harper KD; Sarkar S; Gennari C; Reginster JY; Pols HA; Recker RR; Harris ST; Wu W; Genant HK; Black DM; Eastell R;
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3609-17. PubMed ID: 12161484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raloxifene reduces fractures in postmenopausal women with osteoporosis.
    Reginster JY; Devogelaer JP
    Clin Orthop Relat Res; 2006 Feb; 443():48-54. PubMed ID: 16462425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.
    Ensrud KE; Stock JL; Barrett-Connor E; Grady D; Mosca L; Khaw KT; Zhao Q; Agnusdei D; Cauley JA
    J Bone Miner Res; 2008 Jan; 23(1):112-20. PubMed ID: 17892376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
    Duvernoy CS; Yeo AA; Wong M; Cox DA; Kim HM
    J Womens Health (Larchmt); 2010 Aug; 19(8):1459-65. PubMed ID: 20626269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
    Barrett-Connor E; Grady D; Sashegyi A; Anderson PW; Cox DA; Hoszowski K; Rautaharju P; Harper KD;
    JAMA; 2002 Feb; 287(7):847-57. PubMed ID: 11851576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of vertebral fracture risk with raloxifene.
    Bashore R
    J Fam Pract; 1999 Nov; 48(11):911-2. PubMed ID: 10907630
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis.
    Seeman E; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
    Osteoporos Int; 2006 Feb; 17(2):313-6. PubMed ID: 16217588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention and treatment of osteoporosis in women with breast cancer.
    Mincey BA; Moraghan TJ; Perez EA
    Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [MORE study(raloxifene)].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():442-9. PubMed ID: 15035168
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.
    Riggs BL; Melton LJ
    J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.